Liraglutide 3.0 mg trial investigates efficacy and safety in overweight/obese T2DM patients on basal insulin

Type 2 Diabetes Mellitus (T2DM) is a progressive metabolic disorder often complicated by obesity and insulin resistance. While basal insulin therapy is a cornerstone for glycemic control in advanced T2DM, it frequently leads to weight gain, which can exacerbate insulin resistance and cardiovascular risk. This creates a therapeutic dilemma, as effective glucose lowering often comes at the cost of increased adiposity. There is a significant unmet need for treatments that can improve glycemic control without promoting weight gain, or ideally, by inducing weight loss, particularly in patients already reliant on insulin. Glucagon-like peptide-1 receptor (GLP-1R) agonists like liraglutide offer a promising approach by enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety, leading to both glycemic improvement and weight reduction.

This global Phase 3 clinical trial is designed to investigate the efficacy and safety of liraglutide 3.0 mg in subjects diagnosed with overweight or obesity and Type 2 Diabetes Mellitus who are currently receiving basal insulin treatment. The study's primary objective is to assess the impact of liraglutide 3.0 mg on glycemic control and body weight, alongside a comprehensive evaluation of its safety profile in this specific patient population. Further details regarding the exact study duration, randomization scheme, comparator arm, and specific primary endpoints are not available in the provided abstract.

The abstract for this clinical trial outlines its objectives but does not present any specific results or data points. Therefore, no findings regarding the efficacy or safety of liraglutide 3.0 mg in the target population can be reported at this time. The trial is designed to generate data on glycemic control, body weight changes, and adverse events, but these outcomes have not yet been disclosed in the provided information.